Central Corporation | Soins de la Peau / Produits Quasi-médicamenteuxOEM Manufacturing (Okayama)

À Propos de la Fabrication OEM de Central Corporation

A cosmetics manufacturing and research company established in 1980, offering ultra-small-lot OEM production starting from just 100 units. Creates original brands with custom blending from scratch—cleansers and toners from 60,000 yen, serums and creams from 80,000 yen. Maintains advanced raw materials including umbilical cord blood exosomes and stem cell culture extracts.

Activités Commerciales de Central Corporation

• Central Corporation (株式会社セントラル・コーポレーション) operates primarily in small-batch cosmetics OEM manufacturing under the concept of "Launch products with orders as small as 100 units." The company also engages in test marketing services and research and development of cosmetic raw materials. Specializing in basic skincare and anti-aging cosmetics
• Central Corporation is actively involved in the development of advanced raw materials including growth factors
• stem cell culture media
• and exosomes.

Caractéristiques & Points Forts de Central Corporation

• Ultra-small lot production from 100 units
• proprietary advanced ingredients (stem cells
• exosomes)
• brand launch support from low price points

Informations de Fabrication de Central Corporation

Spécialités de Central Corporation

• Skincare
• anti-aging care
• serums

Certifications & Équipements de Central Corporation

Équipements Principaux

• Emulsification equipment
• filling equipment
• quality inspection equipment

Réalisations de Central Corporation

Implantations de Central Corporation

Historique de l'Entreprise Central Corporation

• —

  Central Corporation was established in September 1980. In 1985, the company pioneered the industry's first small-batch manufacturing system capable of producing 100 units. The ES301 Series was launched in 1987. In 2001, R-Cell Research Institute (Micromolecule Extraction Research Institute) was established in Miyazaki Prefecture. The company completed its nanonization double liposome encapsulation technology in 2008. In 2020, it began importing umbilical cord blood stem cell culture media raw materials, and in 2022, successfully developed domestically-produced stem cell culture media raw materials.

Récompenses et Reconnaissances de Central Corporation

• Social and Cultural Achievement Award (Presented on December 5
• 2011
• by His Imperial Highness Fushimi Hiraki of the former imperial family at Hakuplatai Hassoen in recognition of achievements in small-batch manufacturing)

Catégories Supportées par Central Corporation

FAQ sur Central Corporation